In patients with HER2-positive metastatic breast cancer , the addition of pertuzumab to trastuzumab and docetaxel , as compared with the addition of placebo , significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination .